United States · Platforms & data · MarketBeat
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start

Detailed summary
Ionis Pharmaceuticals (NASDAQ:IONS) remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CEO Brett Monia said at the UBS Global Biopharma Conference. Monia said physicia
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)



